Key Details
Price
$87.25Annual Revenue
$136.19 MAnnual EPS
-$2.24Annual ROE
-44.32%Beta
1.39Events Calendar
Next earnings date:
Feb 27, 2025Recent quarterly earnings:
Oct 28, 2024Recent annual earnings:
Feb 27, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
SAN JOSE, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT), a company specializing in surgical robotics to improve patient care in urology, has announced that its management team will speak at the 36th Annual Piper Sandler Healthcare Conference in New York City. They are set to present on Wednesday, December 4 at 8:30 a.m. Eastern Time.
In the third quarter, PRCT's sales increased by 66% compared to last year, and their gross margins hit a record high of 63%. The management expects sales to reach $223 million this year, with a projected growth of 64%. Their business model guarantees steady revenue and improved efficiency.
Is PROCEPT BioRobotics Corporation (PRCT) a strong choice for momentum investors? Let's investigate.
PROCEPT BioRobotics (PRCT) has received a Zacks Rank #1 (Strong Buy), indicating increased confidence in the company's potential earnings. This could lead to a rise in the stock price soon.
SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT), a company specializing in surgical robotics to improve urology care, has announced a public offering of $175 million in its common stock. Additionally, a selling stockholder plans to give underwriters a 30-day option to buy up to $26.25 million more of the company's shares. The completion of this offering depends on market conditions, and there is no guarantee regarding its timing or terms.
On Monday, PRCT stock from PROCEPT BioRobotics is being traded following the company's announcement of third-quarter earnings that exceeded expectations.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) will hold its Q3 2024 Earnings Conference Call on October 28, 2024, at 8:00 AM ET. The call will feature company representatives including Matt Bacso, Reza Zadno, Sham Shiblaq, and Kevin Waters, along with various conference call participants from different financial institutions. The operator welcomes everyone and notes that all participants are currently in listen-only mode.
PROCEPT BioRobotics Corporation (PRCT) reported a quarterly loss of $0.40 per share, which is better than the Zacks Consensus Estimate of a $0.48 loss. This is an improvement compared to a loss of $0.51 per share from the same period last year.
SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a company specializing in surgical robotics aimed at improving patient care in urology, has announced its unaudited financial results for the quarter that ended on September 30, 2024.
PROCEPT BioRobotics (PRCT) is currently considered to be oversold, which means that the intense selling might be coming to an end. Additionally, there is a strong consensus among Wall Street analysts to increase earnings forecasts, which could result in a change in the stock's direction.
FAQ
- What is the primary business of PROCEPT BioRobotics?
- What is the ticker symbol for PROCEPT BioRobotics?
- Does PROCEPT BioRobotics pay dividends?
- What sector is PROCEPT BioRobotics in?
- What industry is PROCEPT BioRobotics in?
- What country is PROCEPT BioRobotics based in?
- When did PROCEPT BioRobotics go public?
- Is PROCEPT BioRobotics in the S&P 500?
- Is PROCEPT BioRobotics in the NASDAQ 100?
- Is PROCEPT BioRobotics in the Dow Jones?
- When was PROCEPT BioRobotics's last earnings report?
- When does PROCEPT BioRobotics report earnings?
- Should I buy PROCEPT BioRobotics stock now?